Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)
Year: 2022
Type: article
Abstract: Chimeric Antigen Receptor (CAR) T cell therapy is a transformative treatment that is being increasingly utilized. The novel mechanism of action lends itself to unique toxic profiles. These toxicities manifest in two forms: cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS). ICANS typically manifests as a toxic encephalopathy with a complex delirium. Seizures have been reported as rare occurrences, with very little detail regarding the clinical presentation, assessment or management [ 1 , 2 , 3 , 4 , 5 ].
Source: Blood Cancer Journal
Authors: Jacqui-Lyn Saw, M. Hasib Sidiqi, Michael Ruff, Sara Hocker, Hassan Alkhateeb, Stephen M. Ansell, N. Nora Bennani, David Dingli, Suzanne R. Hayman, Patrick B. Johnston, Prashant Kapoor, Saad J. Kenderian, Taxiarchis V. Kourelis, Shaji K. Kumar, Jonas Paludo, Mithun V. Shah, Mustaqeem A. Siddiqui, Rahma Warsame, Allison Rosenthal, Marie Grill, Januario E. Castro, Jason Siegel, Zaid H. Abdel Rahman, Mohamed A. Kharfan-Dabaja, Elson So, Yi Lin
Institutions: Mayo Clinic, Mayo Clinic Hospital, Mayo Clinic in Florida
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,590
Funders: Nature, National Cancer Institute
OpenAlex ID: W4223631801